2Rosell R.Predicting response to Paclitaxol/Carboplatin -based therapy in NSCLC[J].Seminars in oncology,2002,28(4suppl 14):37～44.
3Rosell R.Pharmacogenomic research and serum DNA analysis in the treatment of non-smsll cell lung cancer[J].Rev Oncologia,2001,38:60～71.
4Kumagai A,Dunphy WG.Purification and molecular cloning of Plx1,a Cdc25-regulatory Kinase from Xenopus egg extracts[J].Science,1996,273(6):1377～1380.
5Rosell R.Determinants of response and resistance of cytotoxics[J].Semin Oncol,2002,291 suppl(4):110～118.
6Hou SM,Ryk C,Kannio A,et al.Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors[J].Environ Mol Mutagen,2003,41(1):37～42.
7Hu Z,Wei Q,Wang X,et al.DNA repair gene XPD polymorphism and lung cancer risk:a meta-analysis[J].Lung Cancer,2004,46(1):1～10.
8HDavid J,Park,Stoehlmacher J,et al.A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum -based chemotherapy in patients with advanced colorectal cancer[J].Cancer Research,2001,15:8654～8658.
9Camps C,Sarries C,Roig B.Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients[J].Clin Lung Cancer,2003,4(4):237～241.
10Rosell R,Crino L,Danenberg K.Targeted therapy in combination with gemcitabine in non-small cell lung cancer[J].Semin Oncol,2003,30(4 Suppl 10):19～25.
6Hou SM, Ryk C, KannioA, et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors[J].Environ Mol Mutagen, 2003, 1 (41) : 37 -42.
7Hemminki K,Xu G, Angelini S,et al. XPD exon 10 and 23 polymorphisms and DNA repair in human skin in situ[J]. Carcinogenesis,2008,22( 15 ) :1185 - 1188.
8Zhou W, Gurubhagavatula S, Liu G,et al. Excision repair crosscomplcmentation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy[J].Clin Cancer Res, 2004, 10 (15) : 4939 -4943.
9Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer[ J ]. Chest,2005, 3 ( 127 ) :978 - 983.
10Lord RV, Brabender J, Gandara D, et al. Low ERCC 1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall cell lung cancer [ J ]. Clin Cancer Res ,2007.8 ( 13 ) : 2286 -2291.
